Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0N7JZ
|
||||
| Former ID |
DIB012408
|
||||
| Drug Name |
SAND-26
|
||||
| Synonyms |
Begedina; CD26-targeting antibody (autoimmunity), ADIENNE
|
||||
| Drug Type |
Antibody
|
||||
| Company |
ADIENNE Pharma & Biotech
|
||||
| Target and Pathway | |||||
| Target(s) | Dipeptidyl peptidase IV | Target Info | [551687] | ||
| KEGG Pathway | Protein digestion and absorption | ||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| References | |||||
| Ref 525143 | ClinicalTrials.gov (NCT02411084) Study of BEGEDINA vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD. U.S. National Institutes of Health. | ||||
| Ref 543248 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8691). | ||||